nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—CYP2D6—Hydroxyurea—head and neck cancer	0.284	0.739	CbGbCtD
Methylphenidate—CYP2D6—Vinblastine—head and neck cancer	0.1	0.261	CbGbCtD
Methylphenidate—Pancytopenia—Vinblastine—head and neck cancer	0.00302	0.00491	CcSEcCtD
Methylphenidate—Euphoric mood—Fluorouracil—head and neck cancer	0.00286	0.00465	CcSEcCtD
Methylphenidate—Pancreatitis—Hydroxyurea—head and neck cancer	0.00285	0.00462	CcSEcCtD
Methylphenidate—Depression—Vinblastine—head and neck cancer	0.00283	0.0046	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Vinblastine—head and neck cancer	0.0028	0.00454	CcSEcCtD
Methylphenidate—Myocardial infarction—Vinblastine—head and neck cancer	0.00278	0.00452	CcSEcCtD
Methylphenidate—Pancytopenia—Hydroxyurea—head and neck cancer	0.00276	0.00448	CcSEcCtD
Methylphenidate—Photosensitivity—Fluorouracil—head and neck cancer	0.00275	0.00447	CcSEcCtD
Methylphenidate—Swelling—Fluorouracil—head and neck cancer	0.00274	0.00445	CcSEcCtD
Methylphenidate—Chest discomfort—Docetaxel—head and neck cancer	0.00272	0.00441	CcSEcCtD
Methylphenidate—Disorientation—Fluorouracil—head and neck cancer	0.0027	0.00439	CcSEcCtD
Methylphenidate—Bone disorder—Docetaxel—head and neck cancer	0.00266	0.00432	CcSEcCtD
Methylphenidate—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00264	0.00429	CcSEcCtD
Methylphenidate—Weight increased—Hydroxyurea—head and neck cancer	0.00264	0.00429	CcSEcCtD
Methylphenidate—Drug interaction—Docetaxel—head and neck cancer	0.00259	0.00421	CcSEcCtD
Methylphenidate—Infestation NOS—Hydroxyurea—head and neck cancer	0.00259	0.0042	CcSEcCtD
Methylphenidate—Infestation—Hydroxyurea—head and neck cancer	0.00259	0.0042	CcSEcCtD
Methylphenidate—Drowsiness—Hydroxyurea—head and neck cancer	0.00259	0.0042	CcSEcCtD
Methylphenidate—Haemoglobin—Vinblastine—head and neck cancer	0.00256	0.00416	CcSEcCtD
Methylphenidate—Haemorrhage—Vinblastine—head and neck cancer	0.00255	0.00414	CcSEcCtD
Methylphenidate—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00254	0.00413	CcSEcCtD
Methylphenidate—Pharyngitis—Vinblastine—head and neck cancer	0.00253	0.00411	CcSEcCtD
Methylphenidate—Inflammation—Docetaxel—head and neck cancer	0.00248	0.00402	CcSEcCtD
Methylphenidate—Lethargy—Fluorouracil—head and neck cancer	0.00247	0.00401	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00245	0.00398	CcSEcCtD
Methylphenidate—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.0024	0.0039	CcSEcCtD
Methylphenidate—Blood pressure increased—Docetaxel—head and neck cancer	0.0024	0.0039	CcSEcCtD
Methylphenidate—Haemoglobin—Hydroxyurea—head and neck cancer	0.00234	0.00379	CcSEcCtD
Methylphenidate—Haemorrhage—Hydroxyurea—head and neck cancer	0.00232	0.00377	CcSEcCtD
Methylphenidate—Hallucination—Hydroxyurea—head and neck cancer	0.00231	0.00375	CcSEcCtD
Methylphenidate—Irritability—Fluorouracil—head and neck cancer	0.00231	0.00375	CcSEcCtD
Methylphenidate—Cardiac arrest—Fluorouracil—head and neck cancer	0.0023	0.00373	CcSEcCtD
Methylphenidate—Skin exfoliation—Docetaxel—head and neck cancer	0.0023	0.00373	CcSEcCtD
Methylphenidate—Alopecia—Vinblastine—head and neck cancer	0.00225	0.00366	CcSEcCtD
Methylphenidate—Neoplasm—Docetaxel—head and neck cancer	0.00217	0.00353	CcSEcCtD
Methylphenidate—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00216	0.00351	CcSEcCtD
Methylphenidate—Angiopathy—Hydroxyurea—head and neck cancer	0.00211	0.00342	CcSEcCtD
Methylphenidate—Chills—Hydroxyurea—head and neck cancer	0.00209	0.00339	CcSEcCtD
Methylphenidate—Ill-defined disorder—Vinblastine—head and neck cancer	0.00206	0.00334	CcSEcCtD
Methylphenidate—Alopecia—Hydroxyurea—head and neck cancer	0.00205	0.00333	CcSEcCtD
Methylphenidate—Anaemia—Vinblastine—head and neck cancer	0.00205	0.00333	CcSEcCtD
Methylphenidate—Angina pectoris—Fluorouracil—head and neck cancer	0.00204	0.00331	CcSEcCtD
Methylphenidate—Erythema—Hydroxyurea—head and neck cancer	0.00202	0.00328	CcSEcCtD
Methylphenidate—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00201	0.00326	CcSEcCtD
Methylphenidate—Malaise—Vinblastine—head and neck cancer	0.002	0.00325	CcSEcCtD
Methylphenidate—Vertigo—Vinblastine—head and neck cancer	0.00199	0.00324	CcSEcCtD
Methylphenidate—Leukopenia—Vinblastine—head and neck cancer	0.00199	0.00322	CcSEcCtD
Methylphenidate—Pancytopenia—Fluorouracil—head and neck cancer	0.00199	0.00322	CcSEcCtD
Methylphenidate—Swelling—Docetaxel—head and neck cancer	0.00198	0.00321	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00194	0.00315	CcSEcCtD
Methylphenidate—Convulsion—Vinblastine—head and neck cancer	0.00192	0.00312	CcSEcCtD
Methylphenidate—Hypertension—Vinblastine—head and neck cancer	0.00192	0.00311	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00191	0.0031	CcSEcCtD
Methylphenidate—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00188	0.00305	CcSEcCtD
Methylphenidate—Pneumonia—Fluorouracil—head and neck cancer	0.00187	0.00304	CcSEcCtD
Methylphenidate—Anaemia—Hydroxyurea—head and neck cancer	0.00187	0.00304	CcSEcCtD
Methylphenidate—Discomfort—Vinblastine—head and neck cancer	0.00187	0.00303	CcSEcCtD
Methylphenidate—Hot flush—Docetaxel—head and neck cancer	0.00187	0.00303	CcSEcCtD
Methylphenidate—Infestation NOS—Fluorouracil—head and neck cancer	0.00186	0.00303	CcSEcCtD
Methylphenidate—Infestation—Fluorouracil—head and neck cancer	0.00186	0.00303	CcSEcCtD
Methylphenidate—Menopausal symptoms—Docetaxel—head and neck cancer	0.00185	0.003	CcSEcCtD
Methylphenidate—Visual disturbance—Docetaxel—head and neck cancer	0.00184	0.00299	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00184	0.00298	CcSEcCtD
Methylphenidate—Myocardial infarction—Fluorouracil—head and neck cancer	0.00183	0.00297	CcSEcCtD
Methylphenidate—Malaise—Hydroxyurea—head and neck cancer	0.00182	0.00296	CcSEcCtD
Methylphenidate—Conjunctivitis—Fluorouracil—head and neck cancer	0.00181	0.00294	CcSEcCtD
Methylphenidate—Leukopenia—Hydroxyurea—head and neck cancer	0.00181	0.00294	CcSEcCtD
Methylphenidate—Lethargy—Docetaxel—head and neck cancer	0.00178	0.00289	CcSEcCtD
Methylphenidate—Thrombocytopenia—Vinblastine—head and neck cancer	0.00177	0.00288	CcSEcCtD
Methylphenidate—Epistaxis—Fluorouracil—head and neck cancer	0.00176	0.00285	CcSEcCtD
Methylphenidate—Convulsion—Hydroxyurea—head and neck cancer	0.00175	0.00285	CcSEcCtD
Methylphenidate—Sinusitis—Fluorouracil—head and neck cancer	0.00175	0.00284	CcSEcCtD
Methylphenidate—Pain in extremity—Docetaxel—head and neck cancer	0.00175	0.00283	CcSEcCtD
Methylphenidate—Anorexia—Vinblastine—head and neck cancer	0.00173	0.0028	CcSEcCtD
Methylphenidate—Migraine—Docetaxel—head and neck cancer	0.00172	0.00279	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00171	0.00278	CcSEcCtD
Methylphenidate—Discomfort—Hydroxyurea—head and neck cancer	0.0017	0.00276	CcSEcCtD
Methylphenidate—Haemoglobin—Fluorouracil—head and neck cancer	0.00168	0.00273	CcSEcCtD
Methylphenidate—Rhinitis—Fluorouracil—head and neck cancer	0.00168	0.00272	CcSEcCtD
Methylphenidate—Haemorrhage—Fluorouracil—head and neck cancer	0.00167	0.00272	CcSEcCtD
Methylphenidate—Pharyngitis—Fluorouracil—head and neck cancer	0.00166	0.0027	CcSEcCtD
Methylphenidate—Oedema—Hydroxyurea—head and neck cancer	0.00165	0.00268	CcSEcCtD
Methylphenidate—Infection—Hydroxyurea—head and neck cancer	0.00164	0.00266	CcSEcCtD
Methylphenidate—Paraesthesia—Vinblastine—head and neck cancer	0.00163	0.00264	CcSEcCtD
Methylphenidate—Dehydration—Docetaxel—head and neck cancer	0.00162	0.00264	CcSEcCtD
Methylphenidate—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00162	0.00263	CcSEcCtD
Methylphenidate—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00162	0.00262	CcSEcCtD
Methylphenidate—Liver function test abnormal—Docetaxel—head and neck cancer	0.00161	0.00262	CcSEcCtD
Methylphenidate—Skin disorder—Hydroxyurea—head and neck cancer	0.0016	0.0026	CcSEcCtD
Methylphenidate—Abdominal pain upper—Docetaxel—head and neck cancer	0.00159	0.00259	CcSEcCtD
Methylphenidate—Breast disorder—Docetaxel—head and neck cancer	0.00158	0.00256	CcSEcCtD
Methylphenidate—Anorexia—Hydroxyurea—head and neck cancer	0.00157	0.00256	CcSEcCtD
Methylphenidate—Decreased appetite—Vinblastine—head and neck cancer	0.00157	0.00256	CcSEcCtD
Methylphenidate—Cramp muscle—Docetaxel—head and neck cancer	0.00157	0.00255	CcSEcCtD
Methylphenidate—Nasopharyngitis—Docetaxel—head and neck cancer	0.00156	0.00253	CcSEcCtD
Methylphenidate—Pain—Vinblastine—head and neck cancer	0.00155	0.00251	CcSEcCtD
Methylphenidate—Constipation—Vinblastine—head and neck cancer	0.00155	0.00251	CcSEcCtD
Methylphenidate—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00154	0.0025	CcSEcCtD
Methylphenidate—Arrhythmia—Fluorouracil—head and neck cancer	0.00149	0.00243	CcSEcCtD
Methylphenidate—Feeling abnormal—Vinblastine—head and neck cancer	0.00149	0.00242	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00148	0.0024	CcSEcCtD
Methylphenidate—Alopecia—Fluorouracil—head and neck cancer	0.00148	0.0024	CcSEcCtD
Methylphenidate—Dyspnoea—Hydroxyurea—head and neck cancer	0.00147	0.00239	CcSEcCtD
Methylphenidate—Angina pectoris—Docetaxel—head and neck cancer	0.00147	0.00239	CcSEcCtD
Methylphenidate—Somnolence—Hydroxyurea—head and neck cancer	0.00147	0.00238	CcSEcCtD
Methylphenidate—Erythema—Fluorouracil—head and neck cancer	0.00146	0.00236	CcSEcCtD
Methylphenidate—Dyspepsia—Hydroxyurea—head and neck cancer	0.00145	0.00236	CcSEcCtD
Methylphenidate—Decreased appetite—Hydroxyurea—head and neck cancer	0.00144	0.00233	CcSEcCtD
Methylphenidate—Pancytopenia—Docetaxel—head and neck cancer	0.00143	0.00233	CcSEcCtD
Methylphenidate—Abdominal pain—Vinblastine—head and neck cancer	0.00143	0.00232	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00143	0.00231	CcSEcCtD
Methylphenidate—Fatigue—Hydroxyurea—head and neck cancer	0.00142	0.00231	CcSEcCtD
Methylphenidate—Pain—Hydroxyurea—head and neck cancer	0.00141	0.00229	CcSEcCtD
Methylphenidate—Constipation—Hydroxyurea—head and neck cancer	0.00141	0.00229	CcSEcCtD
Methylphenidate—Weight increased—Docetaxel—head and neck cancer	0.00137	0.00223	CcSEcCtD
Methylphenidate—Vision blurred—Fluorouracil—head and neck cancer	0.00137	0.00223	CcSEcCtD
Methylphenidate—Weight decreased—Docetaxel—head and neck cancer	0.00136	0.00222	CcSEcCtD
Methylphenidate—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00136	0.00221	CcSEcCtD
Methylphenidate—Pneumonia—Docetaxel—head and neck cancer	0.00135	0.0022	CcSEcCtD
Methylphenidate—Anaemia—Fluorouracil—head and neck cancer	0.00135	0.00219	CcSEcCtD
Methylphenidate—Infestation NOS—Docetaxel—head and neck cancer	0.00135	0.00218	CcSEcCtD
Methylphenidate—Infestation—Docetaxel—head and neck cancer	0.00135	0.00218	CcSEcCtD
Methylphenidate—Hypersensitivity—Vinblastine—head and neck cancer	0.00133	0.00217	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.00133	0.00217	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00133	0.00215	CcSEcCtD
Methylphenidate—Myocardial infarction—Docetaxel—head and neck cancer	0.00132	0.00214	CcSEcCtD
Methylphenidate—Conjunctivitis—Docetaxel—head and neck cancer	0.00131	0.00212	CcSEcCtD
Methylphenidate—Body temperature increased—Hydroxyurea—head and neck cancer	0.00131	0.00212	CcSEcCtD
Methylphenidate—Leukopenia—Fluorouracil—head and neck cancer	0.0013	0.00212	CcSEcCtD
Methylphenidate—Asthenia—Vinblastine—head and neck cancer	0.0013	0.00211	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00127	0.00207	CcSEcCtD
Methylphenidate—Epistaxis—Docetaxel—head and neck cancer	0.00127	0.00206	CcSEcCtD
Methylphenidate—Convulsion—Fluorouracil—head and neck cancer	0.00126	0.00205	CcSEcCtD
Methylphenidate—Chest pain—Fluorouracil—head and neck cancer	0.00124	0.00201	CcSEcCtD
Methylphenidate—Myalgia—Fluorouracil—head and neck cancer	0.00124	0.00201	CcSEcCtD
Methylphenidate—Diarrhoea—Vinblastine—head and neck cancer	0.00124	0.00201	CcSEcCtD
Methylphenidate—Discomfort—Fluorouracil—head and neck cancer	0.00123	0.00199	CcSEcCtD
Methylphenidate—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00122	0.00198	CcSEcCtD
Methylphenidate—Haemoglobin—Docetaxel—head and neck cancer	0.00121	0.00197	CcSEcCtD
Methylphenidate—Rhinitis—Docetaxel—head and neck cancer	0.00121	0.00197	CcSEcCtD
Methylphenidate—Haemorrhage—Docetaxel—head and neck cancer	0.00121	0.00196	CcSEcCtD
Methylphenidate—Confusional state—Fluorouracil—head and neck cancer	0.0012	0.00195	CcSEcCtD
Methylphenidate—Pharyngitis—Docetaxel—head and neck cancer	0.0012	0.00195	CcSEcCtD
Methylphenidate—Dizziness—Vinblastine—head and neck cancer	0.0012	0.00194	CcSEcCtD
Methylphenidate—Urinary tract disorder—Docetaxel—head and neck cancer	0.00119	0.00194	CcSEcCtD
Methylphenidate—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00119	0.00193	CcSEcCtD
Methylphenidate—Oedema—Fluorouracil—head and neck cancer	0.00119	0.00193	CcSEcCtD
Methylphenidate—Connective tissue disorder—Docetaxel—head and neck cancer	0.00119	0.00193	CcSEcCtD
Methylphenidate—Asthenia—Hydroxyurea—head and neck cancer	0.00118	0.00192	CcSEcCtD
Methylphenidate—Urethral disorder—Docetaxel—head and neck cancer	0.00118	0.00192	CcSEcCtD
Methylphenidate—Infection—Fluorouracil—head and neck cancer	0.00118	0.00192	CcSEcCtD
Methylphenidate—Nervous system disorder—Fluorouracil—head and neck cancer	0.00117	0.00189	CcSEcCtD
Methylphenidate—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00116	0.00189	CcSEcCtD
Methylphenidate—Visual impairment—Docetaxel—head and neck cancer	0.00116	0.00189	CcSEcCtD
Methylphenidate—Tachycardia—Fluorouracil—head and neck cancer	0.00116	0.00188	CcSEcCtD
Methylphenidate—Vomiting—Vinblastine—head and neck cancer	0.00115	0.00187	CcSEcCtD
Methylphenidate—Erythema multiforme—Docetaxel—head and neck cancer	0.00114	0.00185	CcSEcCtD
Methylphenidate—Headache—Vinblastine—head and neck cancer	0.00113	0.00184	CcSEcCtD
Methylphenidate—Anorexia—Fluorouracil—head and neck cancer	0.00113	0.00184	CcSEcCtD
Methylphenidate—Diarrhoea—Hydroxyurea—head and neck cancer	0.00113	0.00183	CcSEcCtD
Methylphenidate—Eye disorder—Docetaxel—head and neck cancer	0.00113	0.00183	CcSEcCtD
Methylphenidate—Flushing—Docetaxel—head and neck cancer	0.00112	0.00182	CcSEcCtD
Methylphenidate—Cardiac disorder—Docetaxel—head and neck cancer	0.00112	0.00182	CcSEcCtD
Methylphenidate—Angiopathy—Docetaxel—head and neck cancer	0.0011	0.00178	CcSEcCtD
Methylphenidate—Dizziness—Hydroxyurea—head and neck cancer	0.00109	0.00177	CcSEcCtD
Methylphenidate—Immune system disorder—Docetaxel—head and neck cancer	0.00109	0.00177	CcSEcCtD
Methylphenidate—Mediastinal disorder—Docetaxel—head and neck cancer	0.00109	0.00177	CcSEcCtD
Methylphenidate—Chills—Docetaxel—head and neck cancer	0.00108	0.00176	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00108	0.00176	CcSEcCtD
Methylphenidate—Arrhythmia—Docetaxel—head and neck cancer	0.00108	0.00175	CcSEcCtD
Methylphenidate—Nausea—Vinblastine—head and neck cancer	0.00108	0.00175	CcSEcCtD
Methylphenidate—Insomnia—Fluorouracil—head and neck cancer	0.00108	0.00175	CcSEcCtD
Methylphenidate—Paraesthesia—Fluorouracil—head and neck cancer	0.00107	0.00173	CcSEcCtD
Methylphenidate—Alopecia—Docetaxel—head and neck cancer	0.00107	0.00173	CcSEcCtD
Methylphenidate—Dyspnoea—Fluorouracil—head and neck cancer	0.00106	0.00172	CcSEcCtD
Methylphenidate—Mental disorder—Docetaxel—head and neck cancer	0.00106	0.00172	CcSEcCtD
Methylphenidate—Somnolence—Fluorouracil—head and neck cancer	0.00106	0.00172	CcSEcCtD
Methylphenidate—Erythema—Docetaxel—head and neck cancer	0.00105	0.00171	CcSEcCtD
Methylphenidate—Malnutrition—Docetaxel—head and neck cancer	0.00105	0.00171	CcSEcCtD
Methylphenidate—Vomiting—Hydroxyurea—head and neck cancer	0.00105	0.0017	CcSEcCtD
Methylphenidate—Dyspepsia—Fluorouracil—head and neck cancer	0.00105	0.0017	CcSEcCtD
Methylphenidate—Rash—Hydroxyurea—head and neck cancer	0.00104	0.00169	CcSEcCtD
Methylphenidate—Dermatitis—Hydroxyurea—head and neck cancer	0.00104	0.00169	CcSEcCtD
Methylphenidate—Headache—Hydroxyurea—head and neck cancer	0.00103	0.00168	CcSEcCtD
Methylphenidate—Decreased appetite—Fluorouracil—head and neck cancer	0.00103	0.00168	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00103	0.00167	CcSEcCtD
Methylphenidate—Back pain—Docetaxel—head and neck cancer	0.00102	0.00165	CcSEcCtD
Methylphenidate—Pain—Fluorouracil—head and neck cancer	0.00102	0.00165	CcSEcCtD
Methylphenidate—Muscle spasms—Docetaxel—head and neck cancer	0.00101	0.00164	CcSEcCtD
Methylphenidate—Nausea—Hydroxyurea—head and neck cancer	0.000981	0.00159	CcSEcCtD
Methylphenidate—Feeling abnormal—Fluorouracil—head and neck cancer	0.00098	0.00159	CcSEcCtD
Methylphenidate—Anaemia—Docetaxel—head and neck cancer	0.000972	0.00158	CcSEcCtD
Methylphenidate—Urticaria—Fluorouracil—head and neck cancer	0.000944	0.00153	CcSEcCtD
Methylphenidate—Syncope—Docetaxel—head and neck cancer	0.000943	0.00153	CcSEcCtD
Methylphenidate—Leukopenia—Docetaxel—head and neck cancer	0.000941	0.00153	CcSEcCtD
Methylphenidate—Body temperature increased—Fluorouracil—head and neck cancer	0.00094	0.00153	CcSEcCtD
Methylphenidate—Palpitations—Docetaxel—head and neck cancer	0.000929	0.00151	CcSEcCtD
Methylphenidate—Loss of consciousness—Docetaxel—head and neck cancer	0.000924	0.0015	CcSEcCtD
Methylphenidate—Cough—Docetaxel—head and neck cancer	0.000917	0.00149	CcSEcCtD
Methylphenidate—Convulsion—Docetaxel—head and neck cancer	0.000911	0.00148	CcSEcCtD
Methylphenidate—Hypertension—Docetaxel—head and neck cancer	0.000908	0.00147	CcSEcCtD
Methylphenidate—Chest pain—Docetaxel—head and neck cancer	0.000895	0.00145	CcSEcCtD
Methylphenidate—Myalgia—Docetaxel—head and neck cancer	0.000895	0.00145	CcSEcCtD
Methylphenidate—Arthralgia—Docetaxel—head and neck cancer	0.000895	0.00145	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000889	0.00144	CcSEcCtD
Methylphenidate—Hypersensitivity—Fluorouracil—head and neck cancer	0.000876	0.00142	CcSEcCtD
Methylphenidate—Dry mouth—Docetaxel—head and neck cancer	0.000875	0.00142	CcSEcCtD
Methylphenidate—Confusional state—Docetaxel—head and neck cancer	0.000865	0.0014	CcSEcCtD
Methylphenidate—Oedema—Docetaxel—head and neck cancer	0.000858	0.00139	CcSEcCtD
Methylphenidate—Anaphylactic shock—Docetaxel—head and neck cancer	0.000858	0.00139	CcSEcCtD
Methylphenidate—Infection—Docetaxel—head and neck cancer	0.000852	0.00138	CcSEcCtD
Methylphenidate—Shock—Docetaxel—head and neck cancer	0.000844	0.00137	CcSEcCtD
Methylphenidate—Nervous system disorder—Docetaxel—head and neck cancer	0.000841	0.00137	CcSEcCtD
Methylphenidate—Pruritus—Fluorouracil—head and neck cancer	0.000841	0.00137	CcSEcCtD
Methylphenidate—Thrombocytopenia—Docetaxel—head and neck cancer	0.00084	0.00136	CcSEcCtD
Methylphenidate—Tachycardia—Docetaxel—head and neck cancer	0.000837	0.00136	CcSEcCtD
Methylphenidate—Skin disorder—Docetaxel—head and neck cancer	0.000833	0.00135	CcSEcCtD
Methylphenidate—Anorexia—Docetaxel—head and neck cancer	0.000818	0.00133	CcSEcCtD
Methylphenidate—Diarrhoea—Fluorouracil—head and neck cancer	0.000813	0.00132	CcSEcCtD
Methylphenidate—Dizziness—Fluorouracil—head and neck cancer	0.000786	0.00128	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000782	0.00127	CcSEcCtD
Methylphenidate—Insomnia—Docetaxel—head and neck cancer	0.000776	0.00126	CcSEcCtD
Methylphenidate—Paraesthesia—Docetaxel—head and neck cancer	0.00077	0.00125	CcSEcCtD
Methylphenidate—Dyspnoea—Docetaxel—head and neck cancer	0.000765	0.00124	CcSEcCtD
Methylphenidate—Somnolence—Docetaxel—head and neck cancer	0.000763	0.00124	CcSEcCtD
Methylphenidate—Vomiting—Fluorouracil—head and neck cancer	0.000756	0.00123	CcSEcCtD
Methylphenidate—Dyspepsia—Docetaxel—head and neck cancer	0.000755	0.00123	CcSEcCtD
Methylphenidate—Rash—Fluorouracil—head and neck cancer	0.00075	0.00122	CcSEcCtD
Methylphenidate—Dermatitis—Fluorouracil—head and neck cancer	0.000749	0.00122	CcSEcCtD
Methylphenidate—Decreased appetite—Docetaxel—head and neck cancer	0.000746	0.00121	CcSEcCtD
Methylphenidate—Headache—Fluorouracil—head and neck cancer	0.000745	0.00121	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000741	0.0012	CcSEcCtD
Methylphenidate—Fatigue—Docetaxel—head and neck cancer	0.00074	0.0012	CcSEcCtD
Methylphenidate—Pain—Docetaxel—head and neck cancer	0.000734	0.00119	CcSEcCtD
Methylphenidate—Constipation—Docetaxel—head and neck cancer	0.000734	0.00119	CcSEcCtD
Methylphenidate—Feeling abnormal—Docetaxel—head and neck cancer	0.000707	0.00115	CcSEcCtD
Methylphenidate—Nausea—Fluorouracil—head and neck cancer	0.000706	0.00115	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000702	0.00114	CcSEcCtD
Methylphenidate—Abdominal pain—Docetaxel—head and neck cancer	0.000678	0.0011	CcSEcCtD
Methylphenidate—Body temperature increased—Docetaxel—head and neck cancer	0.000678	0.0011	CcSEcCtD
Methylphenidate—Hypersensitivity—Docetaxel—head and neck cancer	0.000632	0.00103	CcSEcCtD
Methylphenidate—Asthenia—Docetaxel—head and neck cancer	0.000616	0.000999	CcSEcCtD
Methylphenidate—Pruritus—Docetaxel—head and neck cancer	0.000607	0.000985	CcSEcCtD
Methylphenidate—Diarrhoea—Docetaxel—head and neck cancer	0.000587	0.000953	CcSEcCtD
Methylphenidate—Dizziness—Docetaxel—head and neck cancer	0.000567	0.000921	CcSEcCtD
Methylphenidate—Vomiting—Docetaxel—head and neck cancer	0.000546	0.000886	CcSEcCtD
Methylphenidate—Rash—Docetaxel—head and neck cancer	0.000541	0.000878	CcSEcCtD
Methylphenidate—Dermatitis—Docetaxel—head and neck cancer	0.00054	0.000877	CcSEcCtD
Methylphenidate—Headache—Docetaxel—head and neck cancer	0.000537	0.000873	CcSEcCtD
Methylphenidate—Nausea—Docetaxel—head and neck cancer	0.00051	0.000827	CcSEcCtD
